Vacant Post-Lung Transplant Market Is Big Opportunity For Breath Therapeutics

 
• By Sukaina Virji

Where else would you find a 50% five-year mortality rate and no approved drugs? Investors are confident of the significant commercial potential for Breath Therapeutics' drug/device combo that tackles the main cause of poor mortality after lung transplantation. A €43.5m series A to finance Phase III testing has been secured.

Breath Therapeutics has been spun-out from German firm Pari Pharma GMBH with a €43.5m series A round led by Gimv and Sofinnova Partners, and including Gilde Healthcare.

Graziano Seghezzi, partner at Sofinnova, told Scrip that Bronchiolitis Obliterans Syndrome (BOS), a lethal orphan respiratory disease mainly affecting lung transplant patients, is currently the company's sole target indication

More from Start-Ups & SMEs

More from Business